Erratum: Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: Prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions (Clinical Research in Cardiology (2010) DOI: 10.1007/s00392-010-0179-x);Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: Prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions

Clinical Research in Cardiology

Volumn 99, Issue 11, 2010, Pages 743-752

  Geisler, Tobias ^a   Mueller, Karin ^a   Aichele, Simon ^a   Bigalke, Boris ^a   Stellos, Konstantinos ^a   Htun, Patrick ^a   Ninci, Elena ^a   Fateh Moghadam, Susanne ^a   May, Andreas E ^a   Gawaz, Meinrad ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antiplatelet drug responsiveness; Aspirin; Clopidogrel; Diabetes; Inflammation; PCI

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

EID: 78649649127     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0203-1     Document Type: Erratum

References (46)

1. D Tschoepe 1995 The activated megakariocyte-platelet system in vascular disease: focus on diabetes Semin Thromb Hemost 21 2 152 160 1:STN:280: DyaK2MzovFWrsw%3D%3D 10.1055/s-2007-1000390 7660137
2. JA Beckman MA Creager P Libby 2002 Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2570 2581 1:CAS:528:DC%2BD38Xjs1GltLc%3D 10.1001/jama.287.19.2570 12020339
3. S Fateh-Moghadam Z Li S Ersel, et al. 2005 Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2 Arterioscler Thromb Vasc Biol 25 6 1299 1303 1:CAS:528:DC%2BD2MXksVWqtbs%3D 10.1161/01.ATV.0000165699.41301.c5 15817881 (Pubitemid 40776625)
4. Tschoepe D, Schultheiss HP, Kolarov P et al (1993) Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 88(1):37-42
5. D Tschoepe P Roesen J Esser 1991 Large platelets circulate in an activated state in diabetes mellitus Semin Thromb Hemost 13 857 862
6. MM Bern 1978 Platelet function in diabetes mellitus Diabetes 27 342 350 1:CAS:528:DyaE1cXhvVOhtL0%3D 346421
7. D Tschoepe P Roesen L Kaufmann, et al. 1990 Evidence for abnormal platelet glycoprotein expression in diabetes mellitus Eur J Clin Invest 20 166 170 1:STN:280:DyaK3c3ns1GntA%3D%3D 2112481
8. N Cabeza Z Li C Schulz, et al. 2004 Surface expression of collagen receptor Fc receptor-γ/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells Diabetes 53 8 2117 2121 1:CAS:528:DC%2BD2cXmtFGqt78%3D 10.2337/diabetes.53.8. 2117 15277394 (Pubitemid 38970763)
9. S Mandal R Sarode S Dash, et al. 1993 Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed non insulin-dependent diabetes mellitus Am J Clin Pathol 100 103 107 1:STN:280:DyaK3szmt1KitQ%3D%3D 8356939
10. D Tschoepe E Driesch B Schwippert, et al. 1995 Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia Diabetes 44 890 894 1:CAS:528: DyaK2MXnsVSnsbY%3D 10.2337/diabetes.44.8.890 7542611
11. SM Haffner S Lehto T Rönnemaa, et al. 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction N Engl J Med 339 229 234 1:STN:280:DyaK1czivVKgsg%3D%3D 10.1056/NEJM199807233390404 9673301 (Pubitemid 28350165)
12. CB Granger RM Califf S Young, et al. 1993 Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group J Am Coll Cardiol 21 4 920 925 1:STN:280:DyaK3s7psFWqsA%3D%3D 10.1016/0735-1097(93)90348-5 8450161
13. DK McGuire H Emanuelsson CB Granger, et al. 2000 Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-2b Study, GUSTO 2b Investigators Eur Heart J 21 21 1750 1758 1:STN:280:DC%2BD3M%2FpslyisA%3D%3D 10.1053/euhj.2000.2317 11052839
14. Olson T, Vitanen M, Asplund K et al (1990) Prognosis after stroke in diabetic patients: a controlled prospective study. Diabetologia 33:244-249
15. J Aoki AJ Lansky R Mehran, et al. 2009 Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the acute catheterization and urgent intervention triage strategy trial Circulation 119 5 687 698 1:CAS:528:DC%2BD1MXht1Gmuro%3D 10.1161/CIRCULATIONAHA. 108.804203 19171852
16. DJ Angiolillo A Fernandez-Ortiz E Bernardo, et al. 2005 Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 8 2430 2435 1:CAS:528:DC%2BD2MXnt1ynt70%3D 10.2337/diabetes.54.8.2430 16046311 (Pubitemid 41134272)
17. K Esposito F Nappo R Marfella, et al. 2002 Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress Circulation 106 16 2067 2072 1:CAS:528:DC%2BD38Xns1SnsL4%3D 10.1161/01.CIR.0000034509.14906.AE 12379575 (Pubitemid 35192812)
18. AD Pradhan JE Manson N Rifai, et al. 2001 C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 3 327 334 1:STN:280:DC%2BD3MvisVCmug%3D%3D 10.1001/jama.286.3.327 11466099
19. AE May T Kälsch S Massberg, et al. 2002 Engagement of glycoprotein 2b/2Ia (alpha(2b)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells Circulation 106 16 2111 2117 1:CAS:528:DC%2BD38Xns1Sns7s%3D 10.1161/01.CIR.0000033597.45947.0F 12379582 (Pubitemid 35192818)
20. I Müller M Seyfarth S Rudiger, et al. 2001 Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement Heart 85 1 92 93 10.1136/heart.85.1.92 11119474 (Pubitemid 32973418)
21. W Hochholzer D Trenk D Frundi, et al. 2005 Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 20 2560 2564 1:CAS:528:DC%2BD2MXkt1Shsbw%3D 10.1161/01.CIR.0000160869.75810.98 15809367 (Pubitemid 40740853)
22. M Gawaz A Ruf FJ Neumann, et al. 1998 Effect of glycoprotein 2b-2Ia receptor antagonism on platelet membrane glycoproteins after coronary stent placement Thromb Haemost 80 6 994 1001 1:CAS:528:DyaK1cXotVSlsL4%3D 9869173
23. FJ Neumann W Hochholzer G Pogatsa-Murray, et al. 2001 Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting J Am Coll Cardiol 37 5 1323 1328 1:CAS:528:DC%2BD3MXjtl2ju7g%3D 10.1016/S0735-1097(01)01165-2 11300442 (Pubitemid 32295594)
24. K Thygesen JS Alpert HD White 2007 Joint ESC/ACCF/AHA/WHF Task Force for the redefinition of Myocardial Infarction. Universal definition of myocardial infarction Circulation 116 22 2634 2653 10.1161/CIRCULATIONAHA.107.187397 17951284 (Pubitemid 350182388)
25. M Roffi L Cho DL Bhatt, et al. 2002 Dramatic increase in 30-day mortality in diabetic patients with non-ST segment elevation acute coronary syndromes J Am Coll Cardiol 33 313A 10.1016/S0735-1097(02)81408-5
26. SR Mehta S Yusuf RJ Peters 2001 Clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 527 533 1:CAS:528:DC%2BD3MXmtV2ht7g%3D 10.1016/S0140-6736(01)05701-4 11520521 (Pubitemid 32772726)
27. DL Bhatt KA Fox W Hacke 2006 CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 16 1706 1717 1:CAS:528:DC%2BD28Xjs12gsLk%3D 10.1056/NEJMoa060989 16531616
28. T Geisler M Gawaz 2007 Variable response to clopidogrel in patients with coronary artery disease Semin Thromb Hemost 33 2 196 202 1:CAS:528: DC%2BD2sXktVejtbg%3D 10.1055/s-2007-969034 17340469 (Pubitemid 46427763)
29. Geisler T, Grass D, Bigalke B, Stellos et al (2008) The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 6(1):54-61
30. I Muller F Besta C Schulz, et al. 2003 Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb Haemost 89 5 783 787 1:CAS:528: DC%2BD3sXktlOrs7g%3D 12719773
31. PA Gurbel KP Bliden BL Hiatt, et al. 2003 Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 23 2908 2913 10.1161/01.CIR.0000072771. 11429.83 12796140 (Pubitemid 36736631)
32. T Geisler H Langer M Wydymus, et al. 2006 Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 20 2420 2425 1:CAS:528:DC%2BD28Xht1OksrzF 10.1093/eurheartj/ehl275 17005534 (Pubitemid 44522148)
33. W Hochholzer D Trenk HP Bestehorn, et al. 2006 Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 9 1742 1750 1:CAS:528:DC%2BD28XhtFOjtb7E 10.1016/j.jacc.2006.06.065 17084243 (Pubitemid 44648629)
34. B Hechler M Cattaneo C Gachet 2005 The P2 receptors in platelet function Semin Thromb Hemost 31 2 150 161 1:CAS:528:DC%2BD2MXkvVSnurg%3D 10.1055/s-2005-869520 15852218 (Pubitemid 40605190)
35. DJ Angiolillo 2007 Antiplatelet therapy in type 2 diabetes mellitus Curr Opin Endocrinol Diabetes Obes 14 2 124 131 1:CAS:528:DC%2BD2sXltlOhtr4%3D 17940430
36. D Erlinge C Varenhorst OO Braun S James KJ Winters JA Jakubowski JT Brandt A Sugidachi A Siegbahn L Wallentin 2008 Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo J Am Coll Cardiol 52 24 1968 1977 1:CAS:528:DC%2BD1cXhsVKlsL3M 10.1016/j.jacc.2008.07.068 19055987
37. AI Vinik T Erbas TS Park, et al. 2001 Platelet dysfunction in type 2 diabetes Diabetes Care 24 1476 1485 1:CAS:528:DC%2BD3MXmtlGit7s%3D 10.2337/diacare.24.8.1476 11473089
38. D Tschoepe E Driesch B Schwippert EF Lampeter 1997 Activated platelets in subjects at increased risk of IDDM. DENIS Study Group Deutsche Nikotinamid Interventionsstudie Diabetologia 40 5 573 577 1:CAS:528:DyaK2sXjtVOrsbc%3D 10.1007/s001250050717 9165226 (Pubitemid 27186794)
39. DJ Angiolillo E Bernardo J Palazuelos, et al. 2008 Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study Thromb Haemost 99 1 161 168 1:CAS:528:DC%2BD1cXhtlWisrg%3D 18217149
40. N von Beckerath A Kastrati A Wieczorek, et al. 2007 A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 15 1814 1819 10.1093/eurheartj/ehl489 (Pubitemid 47236637)
41. DJ Angiolillo MA Costa SB Shoemaker, et al. 2008 Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment Am J Cardiol 101 4 440 445 1:CAS:528:DC%2BD1cXhslekt7k%3D 10.1016/j.amjcard.2007.09.087 18312754 (Pubitemid 351210628)
42. DJ Angiolillo SB Shoemaker B Desai, et al. 2007 Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study Circulation 115 6 708 716 1:CAS:528: DC%2BD2sXhtlGqtbg%3D 10.1161/CIRCULATIONAHA.106.667741 17261652 (Pubitemid 46294761)
43. DJ Angiolillo P Capranzano S Goto, et al. 2008 A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur Heart J 29 18 2202 2211 1:CAS:528: DC%2BD1cXht1enu7zO 10.1093/eurheartj/ehn287 18567918
44. T Jernberg CD Payne KJ Winters, et al. 2006 Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 10 1166 1173 1:CAS:528:DC%2BD28Xls1Crt7g%3D 10.1093/eurheartj/ ehi877 16621870
45. JT Brandt CD Payne SD Wiviott, et al. 2007 A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 1 66.e9 66.e16 10.1016/j.ahj.2006.10.010 (Pubitemid 44895531)
46. SD Wiviott E Braunwald DJ Angiolillo for the TRITON-TIMI 38 Investigators 2008 Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Circulation 118 16 1626 1636 1:CAS:528:DC%2BD1cXht1SntLrI 10.1161/CIRCULATIONAHA.108.791061 18757948